<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662685</url>
  </required_header>
  <id_info>
    <org_study_id>Goeckerman Immunogenetics</org_study_id>
    <nct_id>NCT03662685</nct_id>
  </id_info>
  <brief_title>Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris</brief_title>
  <official_title>Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Psoriasis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effect of Goeckerman therapy (a combination of phototherapy and
      topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and
      genetic environment within psoriatic skin lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a three-arm, open-label study to examine the effect of Goeckerman therapy. Goeckerman
      therapy is known for its high efficacy and favorable safety profile in the treatment of
      psoriasis. It consists of a combination of phototherapy and topical crude coal tar). This
      study will examine how Goeckerman therapy, crude coal tar alone, and phototherapy alone
      affect the mmunologic and genetic environment within psoriatic skin lesions. Fifteen subjects
      with moderate to severe psoriasis will be enrolled. Biopsy samples will be collected and
      undergo molecular profiling to further elucidate the mechanism of action by which Goeckerman
      treatment improves psoriatic skin lesions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">November 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 7, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of differentially expressed immune cell populations</measure>
    <time_frame>12 weeks</time_frame>
    <description>Perform quantitative analysis of the immunologic and genetic changes in immune cell populations after treatment with traditional Goeckerman (NBUVB + coal tar), coal tar only, and NB-UVB only, at weeks 2, 4, and 12 compared to baseline week 0. The immunologic profiles will be compared between subjects receiving the traditional Goeckerman therapy (NB-UVB + coal tar), coal tar only, and NB-UVB therapy only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of differentially expressed genes and pathways</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quantify the number of differentially expressed genes in each cell population by RNA-sequencing at weeks 0, 2, 4, 12 after receiving traditional Goeckerman therapy (NB-UVB + coal tar), coal tar only, and NB-UVB therapy only.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Goeckerman Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phototherapy Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crude Coal Tar Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Goeckerman Therapy</intervention_name>
    <description>The Goeckerman regimen consists of exposure to narrowband ultraviolet B (NB-UVB) light phototherapy and application of crude coal tar to the skin 5 days per week. The treatment will occur the UCSF outpatient skin treatment center for approximately 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions). The treatment is consistent with the standard of care Goeckerman treatment protocol at UCSF.</description>
    <arm_group_label>Goeckerman Therapy</arm_group_label>
    <other_name>Combination Treatment with Phototherapy and Crude Coal Tar</other_name>
    <other_name>Goeckerman Regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crude Coal Tar Only</intervention_name>
    <description>A topical medication consisting of crude coal tar will be applied to the psoriatic skin under plastic wrap occlusion for approximately up to 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions), at the outpatient skin treatment center at UCSF.</description>
    <arm_group_label>Crude Coal Tar Only</arm_group_label>
    <other_name>Coal tar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phototherapy Only</intervention_name>
    <description>Light treatment with narrowband ultraviolet B (NB-UVB) phototherapy three days per week for 12 weeks at the UCSF Phototherapy Center per the standard UCSF phototherapy protocol, in which starting dose is based on the subject's Fitzpatrick skin type and gradually increased as tolerated. Each phototherapy treatment will last approximately from under 1 minute to less than 15 minutes.</description>
    <arm_group_label>Phototherapy Only</arm_group_label>
    <other_name>Ultraviolet B</other_name>
    <other_name>Narrowband ultraviolet B</other_name>
    <other_name>NB-UVB</other_name>
    <other_name>UVB phototherapy</other_name>
    <other_name>Phototherapy</other_name>
    <other_name>Light treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Male or female ≥ 18 years of age at enrollment.

          2. Documentation of predominately moderate to severe plaque psoriasis for at least 6
             months prior to enrollment.

          3. Written informed consent obtained from subject and ability for subject to comply with
             the requirements of the study.

          4. Subject is considered a candidate for phototherapy or systemic therapy

          5. Body Surface Area (BSA) ≥ 5%.

          6. Physical exam within clinically acceptable limits.

        Exclusion criteria

          1. Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the patient or the quality of the data.

          2. Subject has predominantly non-plaque form of psoriasis.

          3. Subject has drug-induced psoriasis.

          4. Subject with current, or a history of, severe psoriatic arthritis well controlled on
             current therapy.

          5. Patient has absolute or relative contraindication to phototherapy, including
             photosensitizing disorders.

          6. Evidence of abnormality of any immune cell population from a drug-induced or genetic
             cause.

          7. Known HIV positive status.

          8. Known allergy to lidocaine, other local anesthetics, or any component of local
             anesthetic agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina Bhutani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quinn Thibodeaux, MD</last_name>
    <phone>415-944-7618</phone>
    <email>psoriasis@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristen Beck, MD</last_name>
    <phone>415-944-7618</phone>
    <email>psoriasis@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Psoriasis and Skin Treatment Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quinn Thibodeaux, MD</last_name>
      <phone>415-944-7618</phone>
      <email>psoriasis@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristen Beck, MD</last_name>
      <phone>415-944-7618</phone>
      <email>psoriasis@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gupta R, Debbaneh M, Butler D, Huynh M, Levin E, Leon A, Koo J, Liao W. The Goeckerman regimen for the treatment of moderate to severe psoriasis. J Vis Exp. 2013 Jul 11;(77):e50509. doi: 10.3791/50509.</citation>
    <PMID>23892536</PMID>
  </reference>
  <reference>
    <citation>Menter A, Cram DL. The Goeckerman regimen in two psoriasis day care centers. J Am Acad Dermatol. 1983 Jul;9(1):59-65.</citation>
    <PMID>6886105</PMID>
  </reference>
  <reference>
    <citation>Moscaliuc ML, Heller MM, Lee ES, Koo J. Goeckerman therapy: a very effective, yet often forgotten treatment for severe generalized psoriasis. J Dermatolog Treat. 2013 Feb;24(1):34-7. doi: 10.3109/09546634.2012.658014. Epub 2012 Mar 4.</citation>
    <PMID>22329632</PMID>
  </reference>
  <reference>
    <citation>van den Bogaard EH, Bergboer JG, Vonk-Bergers M, van Vlijmen-Willems IM, Hato SV, van der Valk PG, Schröder JM, Joosten I, Zeeuwen PL, Schalkwijk J. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest. 2013 Feb;123(2):917-27. doi: 10.1172/JCI65642. Epub 2013 Jan 25.</citation>
    <PMID>23348739</PMID>
  </reference>
  <reference>
    <citation>Li B, Tsoi LC, Swindell WR, Gudjonsson JE, Tejasvi T, Johnston A, Ding J, Stuart PE, Xing X, Kochkodan JJ, Voorhees JJ, Kang HM, Nair RP, Abecasis GR, Elder JT. Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms. J Invest Dermatol. 2014 Jul;134(7):1828-1838. doi: 10.1038/jid.2014.28. Epub 2014 Jan 17.</citation>
    <PMID>24441097</PMID>
  </reference>
  <reference>
    <citation>Gupta R, Ahn R, Lai K, Mullins E, Debbaneh M, Dimon M, Arron S, Liao W. Landscape of Long Noncoding RNAs in Psoriatic and Healthy Skin. J Invest Dermatol. 2016 Mar;136(3):603-609. doi: 10.1016/j.jid.2015.12.009. Epub 2015 Dec 18.</citation>
    <PMID>27015450</PMID>
  </reference>
  <reference>
    <citation>Sekhon S, Jeon C, Nakamura M, Afifi L, Yan D, Wu JJ, Liao W, Bhutani T. Review of the mechanism of action of coal tar in psoriasis. J Dermatolog Treat. 2018 May;29(3):230-232. doi: 10.1080/09546634.2017.1369494. Epub 2017 Sep 19. Review. Erratum in: J Dermatolog Treat. 2018 May;29(3):x.</citation>
    <PMID>28814117</PMID>
  </reference>
  <reference>
    <citation>Zhu TH, Nakamura M, Farahnik B, Abrouk M, Singh RK, Lee KM, Hulse S, Koo J, Bhutani T, Liao W. The Patient's Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy. Dermatol Ther (Heidelb). 2016 Sep;6(3):333-9. doi: 10.1007/s13555-016-0132-7. Epub 2016 Jul 29. Review.</citation>
    <PMID>27474032</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>goeckerman</keyword>
  <keyword>phototherapy</keyword>
  <keyword>psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coal Tar</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

